Evidence map›Paper›PMID 40877651›Full record

ArticleBulletin of experimental biology and medicine2025

Arginase-1 and Mer Tyrosine Kinase Expression in Monocyte Populations in Patients with Axial Spondyloarthritis.

L V Sakhno, E Ya Shevela, T V Tyrinova, O Yu Leplina, M A Tikhonova, A Yu Morenkova, O A Chumasova, N A Ilyina, N S Shkaruba, A E Sizikov and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

L V SakhnoResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia. lsahno53@mail.ru.
E Ya ShevelaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
T V TyrinovaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
O Yu LeplinaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
M A TikhonovaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
A Yu MorenkovaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
O A ChumasovaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
N A IlyinaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
N S ShkarubaResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
A E SizikovResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
Yu D KurochkinaResearch Institute of Clinical and Experimental Lymphology - Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.
A V FedorovaResearch Institute of Clinical and Experimental Lymphology - Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.
V O OmelchenkoResearch Institute of Clinical and Experimental Lymphology - Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.
E A LetyaginaResearch Institute of Clinical and Experimental Lymphology - Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.
M A KorolevResearch Institute of Clinical and Experimental Lymphology - Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.
E R ChernykhResearch Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Axial spondyloarthritis is characterized by activation of innate immune cells, which manifested in elevation of classical monocytes and predominance of the proinflammatory phenotype. However, the immunosuppressive potential of monocyte/macrophages remains practically unexplored. We evaluated the expression of Mer tyrosine kinase (MerTK) and arginase-1 (Arg1) in monocyte subsets in patients with axial spondyloarthritis, considering different clinical features. The expression of MerTK and Arg1 in intermediate and non-classical monocytes from patients with axial spondyloarthritis was reduced in comparison with the normal. The most pronounced decrease in monocyte expression of MerTK and Arg1 was associated with a more aggressive course of the disease (presence of coxitis, high disease activity, HLA-B27 positivity) and lack of response to conventional therapy. These data demonstrate an important role of MerTK and Arg1 in limiting myeloid-driven inflammation.

Indexed as

ArginaseAxial Spondyloarthritisc-Mer Tyrosine KinaseMonocytesAdultFemaleHumansMaleMiddle AgedARG1 protein, humanArginasec-Mer Tyrosine KinaseMERTK protein, humanarginase-1axial spondyloarthritismonocytestyrosine kinase Mer

Identifiers

PMID40877651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.